Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INPACT: Improving with Nadroparin the Prognosis in Advanced Cancer Treatment
2005-005336-27Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of low molecular weight heparin calcium in bronchial carcinoma, pancreatic cancer (PC) and prostate cancer (PCa) (2 arms), sponsored by GSK. Primary endpoint: Overall survival (death due to all causes). Started Feb 2006; status: completed.
02
Drugs
low molecular weight heparin calcium
03
Conditions
bronchial carcinomapancreatic cancer (PC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-005336-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005336-27.